We are an AI-enabled, metabolomics-based drug discovery engine for inflammatory disease.
Inflammatory Disease is a huge unmet need. Inflammatory bowel disease, eczema, and rheumatoid arthritis all have millions of patients with billion dollar markets. Despite this, current drugs are poor given the high magnitude and complexity of disease pathology. AI has the potential to break open this space, but currently lacks high quality data sets to train on. Interface Bio’s full-stack pipeline builds these elusive high-quality biological data sets to fully unlock the potential of AI-driven biology for drug discovery.
Interested in learning more? Reach out to hannah@interface.bio